Authorized Generic Drugs: Short and Long-Term Competitive Effects

Edward R. Nelson (Editor)
Jerry G. Wright (Editor)

Series: Pharmacology – Research, Safety Testing and Regulation
BISAC: LAW050020

Clear

$290.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Rising health care costs have for many years focused congressional attention upon the development and availability of prescription drugs. Recently, the presence of “authorized generic” pharmaceuticals in the drug marketplace has been the subject of congressional concern. An “authorized generic” is a pharmaceutical that is marketed by or on behalf of a brand-named drug company, but is sold under a generic name. The brand-name firm may distribute the drug under its own auspices or via a license to a generic drug company. The price of this “authorized copy” is ordinarily lower than that of the brand-name drug. Some sources refer to authorized generics as “branded,” “flanking,” or “pseudo” generics.” This book presents an analysis of the innovation and public health issues relating to authorized generic drugs beginning with a review of the procedures through which independent generic drug companies receive government permission to market their products and resolve patent disputes with brand-name firms and consumer welfare. (Imprint: Nova Biomedical)

Preface

Authorized Generic Drugs: Short-Term Effects and Long-Term Impact
(Federal Trade Commission)

Authorized Generic Pharmaceuticals: Effects on Innovation
(John R. Thomas, CRS)

Index

You have not viewed any product yet.


SHOW ALL OF MY RECENTLY VIEWED BOOKS